151. Health care use and cost of treatment for adolescents and young adults with opioid use disorder.
- Author
-
Orme, Stephen, Zarkin, Gary A., Dunlap, Laura J., Monico, Laura B., Gryczynski, Jan, Fishman, Marc J., Schwartz, Robert P., O'Grady, Kevin E., and Mitchell, Shannon Gwin
- Subjects
- *
NARCOTICS , *SUBSTANCE abuse , *NARCOTIC antagonists , *COUNSELING , *RESEARCH methodology , *MEDICAL care costs , *MEDICAL care use , *RANDOMIZED controlled trials , *COMPARATIVE studies , *DESCRIPTIVE statistics , *STATISTICAL sampling , *ADULTS , *ADOLESCENCE - Abstract
Few studies have examined the cost of medication for opioid use disorder (MOUD) with counseling for the adolescent and young adult population. This study calculated the health care utilization and cost of MOUD treatment, other substance use disorder treatment, and general health care for adolescents and young adults receiving treatment for opioid use disorder. The study randomized youth ages 15 to 21 (N = 288) equally into the two study conditions: extended-release naltrexone (XR-NTX) or treatment as usual (TAU). While participants committed to treatment based on randomization the study observed considerable nonadherence to both randomized conditions. Instead of using the randomly assigned study conditions, we present descriptive costs by the type of MOUD treatment received: XR-NTX only, buprenorphine only, any other combination of MOUD treatments, and no MOUD. Health care use was aggregated over the 6-month period for each participant, and we calculated average/participant utilization for each treatment group. To determine participant costs, we multiplied the unit costs of health care services obtained from the literature by the reported amount of health care utilization for each participant. We then calculated the mean, standard error, median and IQR for MOUD costs, other substance use disorder treatment costs and general healthcare cost from the health care sector perspective. On average, participants in the XR-NTX only group received 2.6 doses of XR-NTX (equivalent to approximately 78 days of treatment). The buprenorphine only group had an average of 97 days of buprenorphine treatment. The XR-NTX only group had higher/patient costs compared to participants in the buprenorphine only group ($10,491 vs. $8765) and higher XR-NTX utilization would further increase costs. Participants in the any other MOUD combination group had the highest total costs ($14,627) while participants in the no MOUD group at the lowest ($3453). Our cost analysis calculates the real-world cost of MOUD treatment and, while not generalizable, provides policy makers an estimate of costs for adolescents and young adults. We found that participants in the XR-NTX only group received fewer days of medication compared to the buprenorphine only group, but their medication costs were higher due to the cost of XR-NTX injections. While the buprenorphine only group had the highest number of days of medication utilization of all the groups, the average number of days of medication utilization was considerably shorter than the six-month treatment period. • Calculated healthcare use and costs for adolescent and young adults with OUD • Significant participant non-adherence to both randomized conditions occurred. • Average utilization of XR-NTX and buprenorphine was well below the 6-month treatment period. • The cost of XR-NTX doses increased average cost despite low average XR-NTX utilization. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF